nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Nilutamide—prostate cancer	0.0857	0.294	CbGbCtD
Epoprostenol—CYP2C9—Bicalutamide—prostate cancer	0.0857	0.294	CbGbCtD
Epoprostenol—CYP2C9—Estrone—prostate cancer	0.0513	0.176	CbGbCtD
Epoprostenol—CYP2C9—Capecitabine—prostate cancer	0.0389	0.134	CbGbCtD
Epoprostenol—CYP2C9—Estradiol—prostate cancer	0.0295	0.101	CbGbCtD
Epoprostenol—PTGIS—prostate gland—prostate cancer	0.00991	0.157	CbGeAlD
Epoprostenol—P2RY12—prostate gland—prostate cancer	0.00893	0.142	CbGeAlD
Epoprostenol—P2RY12—epithelium—prostate cancer	0.00656	0.104	CbGeAlD
Epoprostenol—PTGER1—renal system—prostate cancer	0.00628	0.0998	CbGeAlD
Epoprostenol—PTGIR—prostate gland—prostate cancer	0.00569	0.0904	CbGeAlD
Epoprostenol—CYP2C9—urine—prostate cancer	0.00567	0.09	CbGeAlD
Epoprostenol—PTGIS—testis—prostate cancer	0.00437	0.0694	CbGeAlD
Epoprostenol—PTGIR—epithelium—prostate cancer	0.00418	0.0664	CbGeAlD
Epoprostenol—PTGIR—renal system—prostate cancer	0.00388	0.0616	CbGeAlD
Epoprostenol—PTGIS—lymph node—prostate cancer	0.00317	0.0503	CbGeAlD
Epoprostenol—Bimatoprost—AKR1C3—prostate cancer	0.0026	0.366	CrCbGaD
Epoprostenol—PTGIR—testis—prostate cancer	0.00251	0.0398	CbGeAlD
Epoprostenol—Dinoprost Tromethamine—HPGDS—prostate cancer	0.00193	0.272	CrCbGaD
Epoprostenol—PTGIR—lymph node—prostate cancer	0.00182	0.0289	CbGeAlD
Epoprostenol—Dinoprostone—HPGDS—prostate cancer	0.00148	0.209	CrCbGaD
Epoprostenol—Dinoprostone—SLC22A1—prostate cancer	0.00062	0.0875	CrCbGaD
Epoprostenol—Dinoprostone—CYP19A1—prostate cancer	0.000461	0.065	CrCbGaD
Epoprostenol—Shock—Capecitabine—prostate cancer	0.000106	0.000302	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—prostate cancer	0.000106	0.000301	CcSEcCtD
Epoprostenol—Abdominal pain—Etoposide—prostate cancer	0.000106	0.000301	CcSEcCtD
Epoprostenol—Body temperature increased—Etoposide—prostate cancer	0.000106	0.000301	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—prostate cancer	0.000106	0.000301	CcSEcCtD
Epoprostenol—Nervous system disorder—Capecitabine—prostate cancer	0.000105	0.000301	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—prostate cancer	0.000105	0.000301	CcSEcCtD
Epoprostenol—Thrombocytopenia—Capecitabine—prostate cancer	0.000105	0.0003	CcSEcCtD
Epoprostenol—Syncope—Prednisone—prostate cancer	0.000105	0.0003	CcSEcCtD
Epoprostenol—Tachycardia—Capecitabine—prostate cancer	0.000105	0.000299	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—prostate cancer	0.000105	0.000299	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—prostate cancer	0.000105	0.000298	CcSEcCtD
Epoprostenol—Skin disorder—Capecitabine—prostate cancer	0.000104	0.000298	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—prostate cancer	0.000104	0.000297	CcSEcCtD
Epoprostenol—Hyperhidrosis—Capecitabine—prostate cancer	0.000104	0.000296	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—prostate cancer	0.000104	0.000296	CcSEcCtD
Epoprostenol—Hypotension—Docetaxel—prostate cancer	0.000104	0.000296	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—prostate cancer	0.000104	0.000295	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—prostate cancer	0.000104	0.000295	CcSEcCtD
Epoprostenol—Loss of consciousness—Prednisone—prostate cancer	0.000103	0.000294	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—prostate cancer	0.000102	0.000292	CcSEcCtD
Epoprostenol—Anorexia—Capecitabine—prostate cancer	0.000102	0.000292	CcSEcCtD
Epoprostenol—Nausea—Estradiol—prostate cancer	0.000102	0.000292	CcSEcCtD
Epoprostenol—Vomiting—Mitoxantrone—prostate cancer	0.000102	0.000291	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—prostate cancer	0.000102	0.000291	CcSEcCtD
Epoprostenol—Rash—Mitoxantrone—prostate cancer	0.000101	0.000289	CcSEcCtD
Epoprostenol—Dermatitis—Mitoxantrone—prostate cancer	0.000101	0.000289	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000101	0.000288	CcSEcCtD
Epoprostenol—Headache—Mitoxantrone—prostate cancer	0.000101	0.000287	CcSEcCtD
Epoprostenol—Hypotension—Capecitabine—prostate cancer	0.0001	0.000286	CcSEcCtD
Epoprostenol—Insomnia—Docetaxel—prostate cancer	0.0001	0.000286	CcSEcCtD
Epoprostenol—Myalgia—Prednisone—prostate cancer	9.99e-05	0.000285	CcSEcCtD
Epoprostenol—Arthralgia—Prednisone—prostate cancer	9.99e-05	0.000285	CcSEcCtD
Epoprostenol—Paraesthesia—Docetaxel—prostate cancer	9.97e-05	0.000284	CcSEcCtD
Epoprostenol—Anxiety—Prednisone—prostate cancer	9.95e-05	0.000284	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—prostate cancer	9.93e-05	0.000283	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	9.92e-05	0.000283	CcSEcCtD
Epoprostenol—Dyspnoea—Docetaxel—prostate cancer	9.9e-05	0.000282	CcSEcCtD
Epoprostenol—Somnolence—Docetaxel—prostate cancer	9.87e-05	0.000282	CcSEcCtD
Epoprostenol—Hypersensitivity—Etoposide—prostate cancer	9.84e-05	0.000281	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—prostate cancer	9.8e-05	0.00028	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Capecitabine—prostate cancer	9.79e-05	0.000279	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—prostate cancer	9.78e-05	0.000279	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—prostate cancer	9.78e-05	0.000279	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—prostate cancer	9.78e-05	0.000279	CcSEcCtD
Epoprostenol—Dyspepsia—Docetaxel—prostate cancer	9.77e-05	0.000279	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—prostate cancer	9.75e-05	0.000278	CcSEcCtD
Epoprostenol—Insomnia—Capecitabine—prostate cancer	9.72e-05	0.000277	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—prostate cancer	9.7e-05	0.000277	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—prostate cancer	9.68e-05	0.000276	CcSEcCtD
Epoprostenol—Paraesthesia—Capecitabine—prostate cancer	9.65e-05	0.000275	CcSEcCtD
Epoprostenol—Decreased appetite—Docetaxel—prostate cancer	9.65e-05	0.000275	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—prostate cancer	9.61e-05	0.000274	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Docetaxel—prostate cancer	9.59e-05	0.000273	CcSEcCtD
Epoprostenol—Asthenia—Etoposide—prostate cancer	9.59e-05	0.000273	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—prostate cancer	9.58e-05	0.000273	CcSEcCtD
Epoprostenol—Dyspnoea—Capecitabine—prostate cancer	9.58e-05	0.000273	CcSEcCtD
Epoprostenol—Anaphylactic shock—Prednisone—prostate cancer	9.58e-05	0.000273	CcSEcCtD
Epoprostenol—Oedema—Prednisone—prostate cancer	9.58e-05	0.000273	CcSEcCtD
Epoprostenol—Fatigue—Docetaxel—prostate cancer	9.57e-05	0.000273	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—prostate cancer	9.56e-05	0.000273	CcSEcCtD
Epoprostenol—Nausea—Mitoxantrone—prostate cancer	9.54e-05	0.000272	CcSEcCtD
Epoprostenol—Infection—Prednisone—prostate cancer	9.51e-05	0.000271	CcSEcCtD
Epoprostenol—Mediastinal disorder—Epirubicin—prostate cancer	9.5e-05	0.000271	CcSEcCtD
Epoprostenol—Constipation—Docetaxel—prostate cancer	9.49e-05	0.000271	CcSEcCtD
Epoprostenol—Pain—Docetaxel—prostate cancer	9.49e-05	0.000271	CcSEcCtD
Epoprostenol—Dyspepsia—Capecitabine—prostate cancer	9.46e-05	0.00027	CcSEcCtD
Epoprostenol—Chills—Epirubicin—prostate cancer	9.46e-05	0.00027	CcSEcCtD
Epoprostenol—Pruritus—Etoposide—prostate cancer	9.45e-05	0.00027	CcSEcCtD
Epoprostenol—Shock—Prednisone—prostate cancer	9.42e-05	0.000269	CcSEcCtD
Epoprostenol—Nervous system disorder—Prednisone—prostate cancer	9.39e-05	0.000268	CcSEcCtD
Epoprostenol—Tachycardia—Prednisone—prostate cancer	9.35e-05	0.000267	CcSEcCtD
Epoprostenol—Decreased appetite—Capecitabine—prostate cancer	9.34e-05	0.000267	CcSEcCtD
Epoprostenol—Skin disorder—Prednisone—prostate cancer	9.3e-05	0.000265	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Capecitabine—prostate cancer	9.28e-05	0.000265	CcSEcCtD
Epoprostenol—Fatigue—Capecitabine—prostate cancer	9.27e-05	0.000264	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisone—prostate cancer	9.26e-05	0.000264	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—prostate cancer	9.23e-05	0.000263	CcSEcCtD
Epoprostenol—Pain—Capecitabine—prostate cancer	9.19e-05	0.000262	CcSEcCtD
Epoprostenol—Constipation—Capecitabine—prostate cancer	9.19e-05	0.000262	CcSEcCtD
Epoprostenol—Diarrhoea—Etoposide—prostate cancer	9.14e-05	0.000261	CcSEcCtD
Epoprostenol—Anorexia—Prednisone—prostate cancer	9.13e-05	0.00026	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Docetaxel—prostate cancer	9.08e-05	0.000259	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—prostate cancer	9.05e-05	0.000258	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—prostate cancer	9.05e-05	0.000258	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—prostate cancer	9.04e-05	0.000258	CcSEcCtD
Epoprostenol—Tension—Epirubicin—prostate cancer	9e-05	0.000257	CcSEcCtD
Epoprostenol—Nervousness—Epirubicin—prostate cancer	8.91e-05	0.000254	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—prostate cancer	8.88e-05	0.000253	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—prostate cancer	8.85e-05	0.000252	CcSEcCtD
Epoprostenol—Dizziness—Etoposide—prostate cancer	8.83e-05	0.000252	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—prostate cancer	8.82e-05	0.000252	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Capecitabine—prostate cancer	8.79e-05	0.000251	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—prostate cancer	8.79e-05	0.000251	CcSEcCtD
Epoprostenol—Abdominal pain—Docetaxel—prostate cancer	8.78e-05	0.00025	CcSEcCtD
Epoprostenol—Body temperature increased—Docetaxel—prostate cancer	8.78e-05	0.00025	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—prostate cancer	8.75e-05	0.00025	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Prednisone—prostate cancer	8.72e-05	0.000249	CcSEcCtD
Epoprostenol—Insomnia—Prednisone—prostate cancer	8.66e-05	0.000247	CcSEcCtD
Epoprostenol—Paraesthesia—Prednisone—prostate cancer	8.6e-05	0.000245	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—prostate cancer	8.54e-05	0.000244	CcSEcCtD
Epoprostenol—Urticaria—Capecitabine—prostate cancer	8.54e-05	0.000244	CcSEcCtD
Epoprostenol—Abdominal pain—Capecitabine—prostate cancer	8.5e-05	0.000242	CcSEcCtD
Epoprostenol—Body temperature increased—Capecitabine—prostate cancer	8.5e-05	0.000242	CcSEcCtD
Epoprostenol—Vomiting—Etoposide—prostate cancer	8.49e-05	0.000242	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—prostate cancer	8.48e-05	0.000242	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—prostate cancer	8.43e-05	0.00024	CcSEcCtD
Epoprostenol—Dyspepsia—Prednisone—prostate cancer	8.43e-05	0.00024	CcSEcCtD
Epoprostenol—Rash—Etoposide—prostate cancer	8.42e-05	0.00024	CcSEcCtD
Epoprostenol—Dermatitis—Etoposide—prostate cancer	8.42e-05	0.00024	CcSEcCtD
Epoprostenol—Headache—Etoposide—prostate cancer	8.37e-05	0.000239	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—prostate cancer	8.37e-05	0.000239	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—prostate cancer	8.33e-05	0.000238	CcSEcCtD
Epoprostenol—Decreased appetite—Prednisone—prostate cancer	8.32e-05	0.000237	CcSEcCtD
Epoprostenol—Fatigue—Prednisone—prostate cancer	8.26e-05	0.000235	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—prostate cancer	8.25e-05	0.000235	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—prostate cancer	8.23e-05	0.000235	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—prostate cancer	8.21e-05	0.000234	CcSEcCtD
Epoprostenol—Constipation—Prednisone—prostate cancer	8.19e-05	0.000234	CcSEcCtD
Epoprostenol—Hypersensitivity—Docetaxel—prostate cancer	8.18e-05	0.000233	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—prostate cancer	8.16e-05	0.000233	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—prostate cancer	8.11e-05	0.000231	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—prostate cancer	8.07e-05	0.00023	CcSEcCtD
Epoprostenol—Cough—Epirubicin—prostate cancer	8.01e-05	0.000228	CcSEcCtD
Epoprostenol—Asthenia—Docetaxel—prostate cancer	7.97e-05	0.000227	CcSEcCtD
Epoprostenol—Nausea—Etoposide—prostate cancer	7.94e-05	0.000226	CcSEcCtD
Epoprostenol—Hypersensitivity—Capecitabine—prostate cancer	7.92e-05	0.000226	CcSEcCtD
Epoprostenol—Pruritus—Docetaxel—prostate cancer	7.86e-05	0.000224	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—prostate cancer	7.85e-05	0.000224	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Prednisone—prostate cancer	7.83e-05	0.000223	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—prostate cancer	7.81e-05	0.000223	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—prostate cancer	7.81e-05	0.000223	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—prostate cancer	7.81e-05	0.000223	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—prostate cancer	7.8e-05	0.000223	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—prostate cancer	7.79e-05	0.000222	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.76e-05	0.000221	CcSEcCtD
Epoprostenol—Asthenia—Capecitabine—prostate cancer	7.71e-05	0.00022	CcSEcCtD
Epoprostenol—Dry mouth—Epirubicin—prostate cancer	7.64e-05	0.000218	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—prostate cancer	7.61e-05	0.000217	CcSEcCtD
Epoprostenol—Urticaria—Prednisone—prostate cancer	7.61e-05	0.000217	CcSEcCtD
Epoprostenol—Pruritus—Capecitabine—prostate cancer	7.61e-05	0.000217	CcSEcCtD
Epoprostenol—Diarrhoea—Docetaxel—prostate cancer	7.6e-05	0.000217	CcSEcCtD
Epoprostenol—Abdominal pain—Prednisone—prostate cancer	7.57e-05	0.000216	CcSEcCtD
Epoprostenol—Body temperature increased—Prednisone—prostate cancer	7.57e-05	0.000216	CcSEcCtD
Epoprostenol—Confusional state—Epirubicin—prostate cancer	7.55e-05	0.000215	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—prostate cancer	7.5e-05	0.000214	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—prostate cancer	7.49e-05	0.000214	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—prostate cancer	7.49e-05	0.000214	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—prostate cancer	7.46e-05	0.000213	CcSEcCtD
Epoprostenol—Infection—Epirubicin—prostate cancer	7.44e-05	0.000212	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—prostate cancer	7.41e-05	0.000211	CcSEcCtD
Epoprostenol—Shock—Epirubicin—prostate cancer	7.37e-05	0.00021	CcSEcCtD
Epoprostenol—Diarrhoea—Capecitabine—prostate cancer	7.36e-05	0.00021	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—prostate cancer	7.34e-05	0.000209	CcSEcCtD
Epoprostenol—Dizziness—Docetaxel—prostate cancer	7.34e-05	0.000209	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—prostate cancer	7.33e-05	0.000209	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—prostate cancer	7.31e-05	0.000208	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—prostate cancer	7.27e-05	0.000207	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—prostate cancer	7.24e-05	0.000206	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—prostate cancer	7.23e-05	0.000206	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—prostate cancer	7.23e-05	0.000206	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—prostate cancer	7.23e-05	0.000206	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—prostate cancer	7.2e-05	0.000205	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	7.18e-05	0.000205	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—prostate cancer	7.14e-05	0.000204	CcSEcCtD
Epoprostenol—Dizziness—Capecitabine—prostate cancer	7.11e-05	0.000203	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—prostate cancer	7.07e-05	0.000202	CcSEcCtD
Epoprostenol—Vomiting—Docetaxel—prostate cancer	7.06e-05	0.000201	CcSEcCtD
Epoprostenol—Hypersensitivity—Prednisone—prostate cancer	7.05e-05	0.000201	CcSEcCtD
Epoprostenol—Rash—Docetaxel—prostate cancer	7e-05	0.0002	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—prostate cancer	7e-05	0.0002	CcSEcCtD
Epoprostenol—Dermatitis—Docetaxel—prostate cancer	6.99e-05	0.000199	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—prostate cancer	6.99e-05	0.000199	CcSEcCtD
Epoprostenol—Headache—Docetaxel—prostate cancer	6.96e-05	0.000198	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—prostate cancer	6.93e-05	0.000198	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—prostate cancer	6.93e-05	0.000198	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—prostate cancer	6.88e-05	0.000196	CcSEcCtD
Epoprostenol—Asthenia—Prednisone—prostate cancer	6.87e-05	0.000196	CcSEcCtD
Epoprostenol—Vomiting—Capecitabine—prostate cancer	6.83e-05	0.000195	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.82e-05	0.000195	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—prostate cancer	6.82e-05	0.000194	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—prostate cancer	6.8e-05	0.000194	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—prostate cancer	6.78e-05	0.000193	CcSEcCtD
Epoprostenol—Rash—Capecitabine—prostate cancer	6.78e-05	0.000193	CcSEcCtD
Epoprostenol—Pruritus—Prednisone—prostate cancer	6.77e-05	0.000193	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—prostate cancer	6.77e-05	0.000193	CcSEcCtD
Epoprostenol—Dermatitis—Capecitabine—prostate cancer	6.77e-05	0.000193	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—prostate cancer	6.76e-05	0.000193	CcSEcCtD
Epoprostenol—Headache—Capecitabine—prostate cancer	6.73e-05	0.000192	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—prostate cancer	6.73e-05	0.000192	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—prostate cancer	6.72e-05	0.000192	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—prostate cancer	6.7e-05	0.000191	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—prostate cancer	6.68e-05	0.00019	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—prostate cancer	6.66e-05	0.00019	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—prostate cancer	6.61e-05	0.000188	CcSEcCtD
Epoprostenol—Nausea—Docetaxel—prostate cancer	6.6e-05	0.000188	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—prostate cancer	6.59e-05	0.000188	CcSEcCtD
Epoprostenol—Diarrhoea—Prednisone—prostate cancer	6.55e-05	0.000187	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—prostate cancer	6.51e-05	0.000186	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—prostate cancer	6.47e-05	0.000185	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—prostate cancer	6.47e-05	0.000184	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—prostate cancer	6.46e-05	0.000184	CcSEcCtD
Epoprostenol—Pain—Epirubicin—prostate cancer	6.4e-05	0.000183	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—prostate cancer	6.4e-05	0.000183	CcSEcCtD
Epoprostenol—Nausea—Capecitabine—prostate cancer	6.39e-05	0.000182	CcSEcCtD
Epoprostenol—Dizziness—Prednisone—prostate cancer	6.33e-05	0.000181	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	6.31e-05	0.00018	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—prostate cancer	6.27e-05	0.000179	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—prostate cancer	6.22e-05	0.000177	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—prostate cancer	6.18e-05	0.000176	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—prostate cancer	6.16e-05	0.000176	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—prostate cancer	6.12e-05	0.000175	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—prostate cancer	6.1e-05	0.000174	CcSEcCtD
Epoprostenol—Vomiting—Prednisone—prostate cancer	6.09e-05	0.000174	CcSEcCtD
Epoprostenol—Rash—Prednisone—prostate cancer	6.04e-05	0.000172	CcSEcCtD
Epoprostenol—Dermatitis—Prednisone—prostate cancer	6.03e-05	0.000172	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—prostate cancer	6.02e-05	0.000172	CcSEcCtD
Epoprostenol—Headache—Prednisone—prostate cancer	6e-05	0.000171	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.98e-05	0.000171	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—prostate cancer	5.97e-05	0.00017	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—prostate cancer	5.95e-05	0.00017	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—prostate cancer	5.93e-05	0.000169	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—prostate cancer	5.93e-05	0.000169	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—prostate cancer	5.92e-05	0.000169	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—prostate cancer	5.92e-05	0.000169	CcSEcCtD
Epoprostenol—Nausea—Prednisone—prostate cancer	5.69e-05	0.000162	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—prostate cancer	5.67e-05	0.000162	CcSEcCtD
Epoprostenol—Hypersensitivity—Epirubicin—prostate cancer	5.52e-05	0.000157	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—prostate cancer	5.5e-05	0.000157	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—prostate cancer	5.48e-05	0.000156	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—prostate cancer	5.48e-05	0.000156	CcSEcCtD
Epoprostenol—Asthenia—Epirubicin—prostate cancer	5.37e-05	0.000153	CcSEcCtD
Epoprostenol—Pruritus—Epirubicin—prostate cancer	5.3e-05	0.000151	CcSEcCtD
Epoprostenol—Diarrhoea—Epirubicin—prostate cancer	5.12e-05	0.000146	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—prostate cancer	5.11e-05	0.000146	CcSEcCtD
Epoprostenol—Asthenia—Doxorubicin—prostate cancer	4.97e-05	0.000142	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—prostate cancer	4.95e-05	0.000141	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—prostate cancer	4.9e-05	0.00014	CcSEcCtD
Epoprostenol—Vomiting—Epirubicin—prostate cancer	4.76e-05	0.000136	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—prostate cancer	4.74e-05	0.000135	CcSEcCtD
Epoprostenol—Rash—Epirubicin—prostate cancer	4.72e-05	0.000135	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—prostate cancer	4.72e-05	0.000135	CcSEcCtD
Epoprostenol—Headache—Epirubicin—prostate cancer	4.69e-05	0.000134	CcSEcCtD
Epoprostenol—Dizziness—Doxorubicin—prostate cancer	4.58e-05	0.000131	CcSEcCtD
Epoprostenol—Nausea—Epirubicin—prostate cancer	4.45e-05	0.000127	CcSEcCtD
Epoprostenol—Vomiting—Doxorubicin—prostate cancer	4.41e-05	0.000126	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—prostate cancer	4.37e-05	0.000125	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—prostate cancer	4.37e-05	0.000124	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—prostate cancer	4.34e-05	0.000124	CcSEcCtD
Epoprostenol—Nausea—Doxorubicin—prostate cancer	4.12e-05	0.000117	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—LEP—prostate cancer	1.63e-05	5.64e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LEP—prostate cancer	1.63e-05	5.64e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CAV1—prostate cancer	1.61e-05	5.59e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CAV1—prostate cancer	1.61e-05	5.59e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CG—prostate cancer	1.59e-05	5.53e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APC—prostate cancer	1.59e-05	5.53e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KDR—prostate cancer	1.59e-05	5.53e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KDR—prostate cancer	1.59e-05	5.53e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—prostate cancer	1.59e-05	5.51e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGF—prostate cancer	1.58e-05	5.47e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IRS1—prostate cancer	1.58e-05	5.47e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—prostate cancer	1.58e-05	5.47e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—prostate cancer	1.57e-05	5.45e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ESR1—prostate cancer	1.55e-05	5.39e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ESR1—prostate cancer	1.55e-05	5.39e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TNFRSF21—prostate cancer	1.54e-05	5.35e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—prostate cancer	1.54e-05	5.35e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GSK3B—prostate cancer	1.53e-05	5.31e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BAD—prostate cancer	1.51e-05	5.26e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BAD—prostate cancer	1.51e-05	5.26e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—EP300—prostate cancer	1.51e-05	5.25e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—INS—prostate cancer	1.51e-05	5.24e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP7B1—prostate cancer	1.5e-05	5.2e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTAP—prostate cancer	1.5e-05	5.2e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CREBBP—prostate cancer	1.48e-05	5.13e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APC—prostate cancer	1.47e-05	5.09e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CG—prostate cancer	1.47e-05	5.09e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CG—prostate cancer	1.47e-05	5.09e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APC—prostate cancer	1.47e-05	5.09e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	1.47e-05	5.08e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SULT1E1—prostate cancer	1.46e-05	5.07e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SRD5A1—prostate cancer	1.46e-05	5.07e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—prostate cancer	1.46e-05	5.07e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—prostate cancer	1.46e-05	5.05e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—prostate cancer	1.45e-05	5.04e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGF—prostate cancer	1.45e-05	5.03e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGF—prostate cancer	1.45e-05	5.03e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IRS1—prostate cancer	1.45e-05	5.03e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IRS1—prostate cancer	1.45e-05	5.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	1.42e-05	4.92e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAP2K1—prostate cancer	1.41e-05	4.9e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GSK3B—prostate cancer	1.41e-05	4.89e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GSK3B—prostate cancer	1.41e-05	4.89e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CD—prostate cancer	1.4e-05	4.86e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	1.4e-05	4.85e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ACSL4—prostate cancer	1.39e-05	4.84e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSD17B3—prostate cancer	1.39e-05	4.84e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—INS—prostate cancer	1.39e-05	4.82e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—INS—prostate cancer	1.39e-05	4.82e-05	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—prostate cancer	1.39e-05	4.82e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SERPINE1—prostate cancer	1.39e-05	4.81e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	1.38e-05	4.78e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—prostate cancer	1.37e-05	4.76e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CREBBP—prostate cancer	1.36e-05	4.72e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CREBBP—prostate cancer	1.36e-05	4.72e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—prostate cancer	1.34e-05	4.66e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—prostate cancer	1.34e-05	4.66e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGF2—prostate cancer	1.34e-05	4.66e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—prostate cancer	1.34e-05	4.64e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—prostate cancer	1.34e-05	4.64e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—prostate cancer	1.34e-05	4.64e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UMPS—prostate cancer	1.34e-05	4.64e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PHGDH—prostate cancer	1.34e-05	4.64e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ARG2—prostate cancer	1.34e-05	4.64e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	1.33e-05	4.61e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOS3—prostate cancer	1.32e-05	4.59e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LDHB—prostate cancer	1.31e-05	4.55e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAP2K1—prostate cancer	1.3e-05	4.51e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAP2K1—prostate cancer	1.3e-05	4.51e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CD—prostate cancer	1.29e-05	4.48e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CD—prostate cancer	1.29e-05	4.48e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP3A5—prostate cancer	1.29e-05	4.46e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JAK2—prostate cancer	1.29e-05	4.46e-05	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—prostate cancer	1.28e-05	4.43e-05	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—prostate cancer	1.28e-05	4.43e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SERPINE1—prostate cancer	1.28e-05	4.43e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SERPINE1—prostate cancer	1.28e-05	4.43e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—prostate cancer	1.26e-05	4.38e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—prostate cancer	1.26e-05	4.38e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—prostate cancer	1.26e-05	4.37e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MDM2—prostate cancer	1.26e-05	4.36e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PDHA1—prostate cancer	1.24e-05	4.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA3—prostate cancer	1.24e-05	4.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TCN2—prostate cancer	1.24e-05	4.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UCP3—prostate cancer	1.24e-05	4.31e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—prostate cancer	1.24e-05	4.3e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGF2—prostate cancer	1.23e-05	4.29e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGF2—prostate cancer	1.23e-05	4.29e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CB—prostate cancer	1.22e-05	4.24e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOS3—prostate cancer	1.22e-05	4.23e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOS3—prostate cancer	1.22e-05	4.23e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSD3B1—prostate cancer	1.19e-05	4.11e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC22A3—prostate cancer	1.19e-05	4.11e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—prostate cancer	1.18e-05	4.11e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JAK2—prostate cancer	1.18e-05	4.11e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JAK2—prostate cancer	1.18e-05	4.11e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—prostate cancer	1.17e-05	4.07e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—prostate cancer	1.16e-05	4.03e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—prostate cancer	1.16e-05	4.03e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MDM2—prostate cancer	1.16e-05	4.01e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MDM2—prostate cancer	1.16e-05	4.01e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.15e-05	3.99e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1B—prostate cancer	1.15e-05	3.98e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—prostate cancer	1.14e-05	3.95e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—prostate cancer	1.14e-05	3.95e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TBXAS1—prostate cancer	1.14e-05	3.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA4—prostate cancer	1.14e-05	3.94e-05	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—prostate cancer	1.13e-05	3.94e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CB—prostate cancer	1.12e-05	3.9e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CB—prostate cancer	1.12e-05	3.9e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—prostate cancer	1.12e-05	3.9e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—prostate cancer	1.12e-05	3.89e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—prostate cancer	1.12e-05	3.89e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—prostate cancer	1.12e-05	3.87e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.11e-05	3.85e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA2—prostate cancer	1.11e-05	3.84e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCG5—prostate cancer	1.09e-05	3.8e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SULT1A1—prostate cancer	1.09e-05	3.8e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—prostate cancer	1.09e-05	3.8e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—prostate cancer	1.09e-05	3.79e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—prostate cancer	1.08e-05	3.76e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—prostate cancer	1.08e-05	3.75e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—prostate cancer	1.08e-05	3.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA1—prostate cancer	1.07e-05	3.71e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—prostate cancer	1.06e-05	3.68e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1A—prostate cancer	1.06e-05	3.67e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTO1—prostate cancer	1.06e-05	3.67e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSD3B2—prostate cancer	1.06e-05	3.67e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NAT2—prostate cancer	1.06e-05	3.67e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—prostate cancer	1.06e-05	3.66e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1B—prostate cancer	1.06e-05	3.66e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1B—prostate cancer	1.06e-05	3.66e-05	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—prostate cancer	1.04e-05	3.62e-05	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—prostate cancer	1.04e-05	3.62e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—prostate cancer	1.03e-05	3.59e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—prostate cancer	1.03e-05	3.59e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—prostate cancer	1.03e-05	3.58e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—prostate cancer	1.03e-05	3.58e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—prostate cancer	1.03e-05	3.57e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—prostate cancer	1.03e-05	3.56e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—prostate cancer	1.03e-05	3.56e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.02e-05	3.52e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLCB2—prostate cancer	1.01e-05	3.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LRP2—prostate cancer	1.01e-05	3.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2C18—prostate cancer	1.01e-05	3.51e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EP300—prostate cancer	1.01e-05	3.49e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—prostate cancer	1.01e-05	3.49e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—prostate cancer	1.01e-05	3.49e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—prostate cancer	9.97e-06	3.46e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—prostate cancer	9.97e-06	3.46e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—P4HB—prostate cancer	9.93e-06	3.45e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SRC—prostate cancer	9.79e-06	3.4e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—prostate cancer	9.77e-06	3.39e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—prostate cancer	9.77e-06	3.39e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1A—prostate cancer	9.74e-06	3.38e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1A—prostate cancer	9.74e-06	3.38e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—prostate cancer	9.71e-06	3.37e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—prostate cancer	9.71e-06	3.37e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC22A1—prostate cancer	9.66e-06	3.35e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	9.55e-06	3.31e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—prostate cancer	9.53e-06	3.31e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—prostate cancer	9.48e-06	3.29e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—prostate cancer	9.48e-06	3.29e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—prostate cancer	9.44e-06	3.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SULT2A1—prostate cancer	9.41e-06	3.27e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EP300—prostate cancer	9.26e-06	3.21e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EP300—prostate cancer	9.26e-06	3.21e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MED12—prostate cancer	9.26e-06	3.21e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNG5—prostate cancer	9.19e-06	3.19e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—prostate cancer	9.15e-06	3.17e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SRC—prostate cancer	9.01e-06	3.13e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SRC—prostate cancer	9.01e-06	3.13e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOA3—prostate cancer	8.85e-06	3.07e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—prostate cancer	8.77e-06	3.04e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—prostate cancer	8.77e-06	3.04e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—prostate cancer	8.77e-06	3.04e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—prostate cancer	8.75e-06	3.04e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	8.7e-06	3.02e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—prostate cancer	8.69e-06	3.01e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—prostate cancer	8.69e-06	3.01e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—prostate cancer	8.58e-06	2.98e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPGDS—prostate cancer	8.44e-06	2.93e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2C19—prostate cancer	8.39e-06	2.91e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—prostate cancer	8.19e-06	2.84e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ACHE—prostate cancer	8.19e-06	2.84e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—prostate cancer	8.11e-06	2.81e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2A6—prostate cancer	8.1e-06	2.81e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—prostate cancer	8.07e-06	2.8e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—prostate cancer	8.07e-06	2.8e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	8.06e-06	2.8e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—prostate cancer	8.05e-06	2.79e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—prostate cancer	8.05e-06	2.79e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—prostate cancer	7.9e-06	2.74e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—prostate cancer	7.9e-06	2.74e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKR1C3—prostate cancer	7.88e-06	2.73e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PRKACB—prostate cancer	7.83e-06	2.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP17A1—prostate cancer	7.75e-06	2.69e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	7.65e-06	2.65e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—prostate cancer	7.46e-06	2.59e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—prostate cancer	7.46e-06	2.59e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—prostate cancer	7.45e-06	2.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOA2—prostate cancer	7.39e-06	2.56e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—prostate cancer	7.2e-06	2.5e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A5—prostate cancer	7.05e-06	2.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2E1—prostate cancer	6.88e-06	2.39e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—prostate cancer	6.85e-06	2.38e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—prostate cancer	6.85e-06	2.38e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NQO1—prostate cancer	6.81e-06	2.36e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TH—prostate cancer	6.71e-06	2.33e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.66e-06	2.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP3A4—prostate cancer	6.64e-06	2.3e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—prostate cancer	6.63e-06	2.3e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—prostate cancer	6.63e-06	2.3e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.6e-06	2.29e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—prostate cancer	6.59e-06	2.29e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1B1—prostate cancer	6.53e-06	2.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GGT1—prostate cancer	6.32e-06	2.19e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOA1—prostate cancer	6.23e-06	2.16e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP19A1—prostate cancer	6.14e-06	2.13e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—prostate cancer	6.08e-06	2.11e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—prostate cancer	6.07e-06	2.11e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—prostate cancer	6.07e-06	2.11e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—RXRA—prostate cancer	5.92e-06	2.05e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.76e-06	2e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—COMT—prostate cancer	5.7e-06	1.98e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—prostate cancer	5.68e-06	1.97e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—prostate cancer	5.6e-06	1.94e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—prostate cancer	5.6e-06	1.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ITPR1—prostate cancer	5.59e-06	1.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.49e-06	1.91e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMS—prostate cancer	5.28e-06	1.83e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—prostate cancer	5.22e-06	1.81e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LPL—prostate cancer	5.12e-06	1.78e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A1—prostate cancer	4.95e-06	1.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ERCC2—prostate cancer	4.9e-06	1.7e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—prostate cancer	4.61e-06	1.6e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARA—prostate cancer	4.52e-06	1.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAV1—prostate cancer	4.25e-06	1.48e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.06e-06	1.41e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CG—prostate cancer	3.87e-06	1.34e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—INS—prostate cancer	3.67e-06	1.27e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CREBBP—prostate cancer	3.59e-06	1.25e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CD—prostate cancer	3.41e-06	1.18e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NOS3—prostate cancer	3.22e-06	1.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CB—prostate cancer	2.97e-06	1.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—prostate cancer	2.94e-06	1.02e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—prostate cancer	2.56e-06	8.9e-06	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—EP300—prostate cancer	2.45e-06	8.49e-06	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.81e-06	6.28e-06	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—prostate cancer	1.48e-06	5.13e-06	CbGpPWpGaD
